The estimated Net Worth of Daniel P Phd Gold is at least $3.24 millió dollars as of 25 May 2021. Daniel Gold owns over 5,000 units of MEI Pharma Inc stock worth over $1,385,069 and over the last 12 years he sold MEIP stock worth over $0. In addition, he makes $1,854,410 as President, Chief Executive Officer és Director at MEI Pharma Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Gold MEIP stock SEC Form 4 insiders trading
Daniel has made over 4 trades of the MEI Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of MEIP stock worth $12,600 on 25 May 2021.
The largest trade he's ever made was exercising 20,000 units of MEI Pharma Inc stock on 27 September 2019 worth over $31,400. On average, Daniel trades about 2,655 units every 29 days since 2012. As of 25 May 2021 he still owns at least 458,632 units of MEI Pharma Inc stock.
You can see the complete history of Daniel Gold stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Gold biography
Dr. Daniel P. Gold Ph.D. serves as President, Chief Executive Officer, Director of the Company. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that advanced the company’s lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold’s academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor’s degree in Biology from the University of California Los Angeles.
What is the salary of Daniel Gold?
As the President, Chief Executive Officer és Director of MEI Pharma Inc, the total compensation of Daniel Gold at MEI Pharma Inc is $1,854,410. There are no executives at MEI Pharma Inc getting paid more.
How old is Daniel Gold?
Daniel Gold is 65, he's been the President, Chief Executive Officer és Director of MEI Pharma Inc since 2010. There are 5 older and 9 younger executives at MEI Pharma Inc. The oldest executive at MEI Pharma Inc is Kevan Clemens, 75, who is the Independent Director.
What's Daniel Gold's mailing address?
Daniel's mailing address filed with the SEC is C/O MEI PHARMA, INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Insiders trading at MEI Pharma Inc
Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L... és Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.
What does MEI Pharma Inc do?
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
What does MEI Pharma Inc's logo look like?
Complete history of Daniel Gold stock trades at MEI Pharma Inc
MEI Pharma Inc executives and stock owners
MEI Pharma Inc executives and other stock owners filed with the SEC include:
-
Daniel Gold,
President, Chief Executive Officer, Director -
David Urso,
Chief Operating Officer, General Counsel -
Dr. Daniel P. Gold,
Pres, CEO & Director -
Brian Drazba,
Chief Financial Officer, Secretary -
David M. Urso B.A., Esq., J.D.,
COO & Gen. Counsel -
Robert Mass,
Chief Medical Officer -
Brian G. Drazba B.A., CPA, CPA,
CFO & Sec. -
Dr. Richard G. Ghalie,
Chief Medical Officer -
Dr. Robert D. Mass,
Strategic Advisor -
Charles Baltic,
Independent Director -
Nicholas Glover,
Independent Director -
Kevan Clemens,
Independent Director -
Frederick Driscoll,
Independent Director -
Tamar Howson,
Independent Director -
Cheryl Cohen,
Director -
Brian Powl,
Senior Vice President of Marketing -
Tina Clark Beamon Esq., J.D.,
Chief Compliance Officer -
Dr. Karen E. Potts Ph.D.,
Sr. VP of Regulatory Affairs -
Dr. Ofir Moreno,
Sr. VP of Pharmaceutical Sciences -
Jamie A. Tereschuck,
VP of HR -
David A. Walsey J.D., L.L.M.,
VP of IR & Corp. Communications -
Leaf Ventures Ii, L.P.New L...,
-
Ventures V, Llc Vivo,
-
Leah Rush Cann,
Director -
Thomas M. Zech,
Chief Financial Officer -
William Dodge Rueckert,
Director -
Ventures Vii, Llc Vivo,
-
Christine Anna White,
Director -
Ventures V, Llc Vivo Ventur...,
-
Leaf Ventures Ii, L.P.New L...,
-
Leaf Ventures Ii, L.P.New L...,
-
Ventures Vii, Llc Vivo Vent...,
-
Josiah T El Coronado Holdin...,
-
Leaf Ventures Ii, L.P.New L...,
-
Josiah T Austin,
10% owner -
Bryan Williams,
Director -
Ltd Novogen,
10% owner -
Sujay Kango,
-
Richard G Ghalie,
Chief Medical Officer -
Thomas C Reynolds,
-
Funds Management Lp Anson A...,
-
Funds, Lp Cable Car Capital...,
-
Steven D Wood,
-
James P Flynn,